SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Tatva Chintan Pharma - Quaterly Results

02 May 2025 Evaluate
The revenue for the March 2025 quarter is pegged at Rs. 1076.48 millions, about 14.60% up against Rs. 939.31 millions recorded during the year-ago period.The company reported a drastic decline of -86.72% in the quarter ended March 2025 to Rs. 10.95  millions from Rs. 82.47 millions  .A decline of 91.98 millions was observed in the OP in the quarter ended March 2025 from 187.25 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 1076.48 939.31 14.60 3664.15 3786.77 -3.24 3664.15 3786.77 -3.24
Other Income 12.95 45.27 -71.39 35.61 75.08 -52.57 35.61 75.08 -52.57
PBIDT 91.98 187.25 -50.88 294.05 743.73 -60.46 294.05 743.73 -60.46
Interest 3.88 2.18 77.98 12.90 65.07 -80.18 12.90 65.07 -80.18
PBDT 88.10 185.07 -52.40 281.15 678.66 -58.57 281.15 678.66 -58.57
Depreciation 72.56 62.31 16.45 276.54 256.01 8.02 276.54 256.01 8.02
PBT 15.54 122.76 -87.34 4.61 422.65 -98.91 4.61 422.65 -98.91
TAX 4.59 40.29 -88.61 1.34 129.17 -98.96 1.34 129.17 -98.96
Deferred Tax 4.73 19.02 -75.13 1.32 55.73 -97.63 1.32 55.73 -97.63
PAT 10.95 82.47 -86.72 3.27 293.48 -98.89 3.27 293.48 -98.89
Equity 233.92 233.92 0.00 233.92 233.92 0.00 233.92 233.92 0.00
PBIDTM(%) 8.54 19.93 -57.14 8.03 19.64 -59.14 8.03 19.64 -59.14

Tatva Chintan Pharma Share Price

1275.10 -8.55 (-0.67%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3703.10
Tata Chemicals 709.05
SRF 2493.65
Pidilite Inds. 1393.25
Deepak Nitrite 1538.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×